Gavi Purchases 414 Million COVID-19 Vaccines from China

China-based Clover Biopharmaceuticals announced an advance purchase agreement with Gavi, the Vaccine Alliance, to provide up to 414 million doses of its protein-based SCB-2019 COVID-19 vaccine candidate (CpG 1018/Alum) for procurement through the COVAX Facility.

Pending an Emergency Use Listing from the World Health Organization for Clover’s COVID-19 vaccine candidate, Clover will make an initial 64 million doses available for procurement through the COVAX Facility in 2021.

Gavi also retains options to procure up to an additional 350 million doses to be delivered in 2022.

“The pandemic continues to evolve, and to be best prepared, COVAX’s actively managed, diverse portfolio will be critical to meeting countries’ needs and protecting against risks such as regulatory delays, variant and supply constraints,” said Dr. Seth Berkley, CEO of Gavi, in a press statement issued on June 30, 2021.

“Today’s agreement with Clover Biopharmaceuticals is yet another important step in that direction.”

The COVAX Facility is a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines that currently includes more than 190 participating economies, designed and administered by Gavi, the Vaccine Alliance.